Carlos Alemany

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

David S. Ettinger, Robert M. Jotte, Paul Lorigan et al. · Journal of Clinical Oncology · 2010 · 124 citations

Medicine, Oncology, Pharmacology +14

Expression of bcl-2 in Classical Hodgkin's Lymphoma: An Independent Predictor of Poor Outcome

Stephen J. Sup, Carlos Alemany, Brad Pohlman et al. · Journal of Clinical Oncology · 2005 · 68 citations · Full text

Medicine, Oncology, Pathology +17

Evaluating the quality of psychosocial care in outpatient medical oncology settings using performance indicators

Paul B. Jacobsen, David Shibata, Erin M. Siegel et al. · Psycho-Oncology · 2010 · 60 citations

Medicine, Oncology, Medical Oncology +5

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

Gayle Jameson, John Hamm, Glen J. Weiss et al. · Clinical Cancer Research · 2012 · 54 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16